Immunology Dysregulation in Lymphadenitis Tuberculosis : An Observational Study Using Patient' Block Paraffins 2019 Until 2021
NCT05202548 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45
Last updated 2022-01-21
Summary
Mycobacterium tuberculosis (M. tuberculosis) infection is still a problem that cannot be overcome in Indonesia. In 2018 the number of tuberculosis (TB) sufferers in Indonesia reached more than 850/100,000 population, an increase around 20% from the previous year's incidence. One of the highest number of cases is in East Java Province, which is 38% of the total number of new TB cases in Indonesia.
Extrapulmonary tuberculosis (EPTB) according to WHO classification criteria is an M. tuberculosis infection that occurs in tissues and organs outside the lung parenchyma. The incidence rate in Indonesia reaches 1-5% of the incidence of TB thus EPTB may often be forgotten. However, the diagnosis, therapy and monitoring post treatment in EPTB remains difficult to do.
The focus of this research is tuberculous lymphadenitis (TB), due to 50% of EPTB cases in Indonesia was lymphadenitis TB. The risk factors for EPTB are immunocompromised conditions, such as HIV infection or comorbid conditions such as chronic kidney disease (CKD) and diabetes mellitus, but the mechanism of EPTB homing is still unclear. The mechanism of EPTB homing, especially TB lymphadenitis, really needs to be known for the development of diagnostics and therapy as well as preventing the occurrence of TB lymphadenitis.
The importance of this research is to obtain compounds from the human immune response that can be developed as diagnostic markers and therapeutic targets for tuberculosis infection, especially TB lymphadenitis. Activated macrophages containing M. tuberculosis are carried by lymph flow to lymph nodes, where there is deposition of antigen-antibody complexes which then activate CC Chemokine Receptor-2 (CCR2) on lymphocytes, which are the primary receptors for Chemokine (CC motif) ligands ( CCL)-8 and CCL5, proteins expressed on macrophages containing M. tuberculosis. Activation of CCR2 increases the production of IL-10(10). IL-10 has been responsible for decreasing the secretion of TNF-, IFN-γ, and IL-1β (11). IFN-γ affects the process of M. tuberculosis elimination and the success of TB therapy, so that IL-10 is responsible for the failure of macrophages to eliminate M. tuberculosis. IL-10 also binds to Signal Transducer and Activator of Transcription 3 (STAT3) and STAT3 increases the release of Suppressor of Cytokine Signaling 3 (SOCS3). SOCS3 interferes with IFN-γ signaling for CCR2 recognition of M. tuberculosis-containing macrophages. On the other hand, the mechanism of T lymphocytes and macrophages that activate pro-inflammatory mediators (TNF-, IFN-γ, and IL-1β) and the association of IL-10 activation on STAT3, SOCS3 and CCR2 expression in the incidence of EPTB, especially TB lymphadenitis without TB infection remains unknown.
Conditions
- Lymphadenitis, Tuberculous
- Immune Defect
Interventions
- OTHER
-
Immuno-histochemical staining
blocked paraffin that suit with inclusion and exclusion criteria proceed with immuno-histochemical staining to define immune dysregulation in lymphadenitis TB
Sponsors & Collaborators
-
Indonesia's Ministry of Research and Technology (Ristekdikti/BRIN)
collaborator UNKNOWN -
Universitas Katolik Widya Mandala Surabaya
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-01
- Primary Completion
- 2021-06-25
- Completion
- 2021-06-25
Countries
- Indonesia
Study Locations
More Related Trials
-
Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary Tuberculosis
NCT01252992 ·Status: COMPLETED
-
TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
NCT03251196 ·Status: UNKNOWN
-
Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
NCT04148053 ·Status: UNKNOWN
-
Immune Response to Mycobacterium Tuberculosis Infection
NCT00257907 ·Status: COMPLETED
-
The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis
NCT06580639 ·Status: RECRUITING
-
A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years
NCT06732583 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Latent Tuberculosis Infection in Bone Marrow Transplant Recipients
NCT01021124 ·Status: COMPLETED
-
Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis
NCT00173264 ·Status: UNKNOWN
-
A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
NCT02606214 ·Status: TERMINATED ·Phase: PHASE1
-
Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy
NCT00811343 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.
NCT00341328 ·Status: COMPLETED ·Phase: PHASE3
-
Diagnosis of Active and Latent TB Infection With IFN-y Assays in African Children
NCT00456469 ·Status: UNKNOWN
-
Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment
NCT04655794 ·Status: UNKNOWN
-
A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)
NCT01049282 ·Status: COMPLETED ·Phase: PHASE1
-
The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA
NCT05005637 ·Status: COMPLETED ·Phase: PHASE2
-
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
NCT02554318 ·Status: COMPLETED ·Phase: NA
-
A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.
NCT03202693 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
NCT02288481 ·Status: COMPLETED ·Phase: PHASE1
-
High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study
NCT02169882 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Oral Vitamin D and Toll Like Receptor in Spondylitis Tuberculosis
NCT05376189 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients
NCT00265226 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness Of Mobile Application To Improve Adherence To Tuberculosis Treatment
NCT05259254 ·Status: UNKNOWN ·Phase: NA
-
Potential Role of Microbiome in Tuberculosis
NCT04985994 ·Status: COMPLETED
-
Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination
NCT01119521 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia
NCT07293455 ·Status: NOT_YET_RECRUITING ·Phase: NA